Non-Hodgkin lymphoma Posts on Medivizor

Evaluating the effectiveness and safety of polatuzumab vedotin combined with dose-adjusted EPOCH-R chemotherapy in patients with aggressive B-cell non-Hodgkin lymphoma.

Posted by Medivizor on Jul 30, 2023 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of polatuzumab vedotin (PV; Polivy) combined with dose-adjusted EPOCH-R chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in patients with aggressive B-cell non-Hodgkin lymphoma (NHL). The data showed that PV combined with dose-adjusted EPOCH-R...

Evaluating the effectiveness and safety of zanubrutinib versus ibrutinib in patients with Waldenström Macroglobulinemia.

Posted by Medivizor on Feb 28, 2023 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of zanubrutinib (Brukinsa) versus ibrutinib (Imbruvica) in patients with Waldenström Macroglobulinemia (WM). The data showed that zanubrutinib had higher long-term response rates and lower side effects than ibrutinib in these patients. Some background WM is a type of cancer in which...

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Posted by Medivizor on Dec 31, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of zanubrutinib (Brukinsa) versus bendamustine (Treanda) plus rituximab (Rituxan) in untreated patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data showed that zanubrutinib significantly improved the survival without cancer worsening versus...

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

Posted by Medivizor on Sep 27, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study assessed the accuracy of whole-body (WB) magnetic resonance imaging (MRI) in evaluating the treatment response of blood cancers. The data indicated that WB-MRI had a high diagnostic performance for assessing the treatment response of blood cancers and its addition was strongly linked to better diagnostic sensitivity. Some...

Evaluating the effectiveness and safety of venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma.

Posted by Medivizor on Sep 18, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding venetoclax (Venclexta) to a dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) regimen as initial therapy in patients with aggressive B-cell lymphoma. The data showed that venetoclax with dose-adjusted EPOCH-R was effective...

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Posted by Medivizor on Sep 1, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...

Evaluating response to SARS-CoV-2 vaccination in patients with blood cancers

Posted by Medivizor on Aug 26, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study aimed to investigate the rate of response (seroconversion) to SARS-Cov-2 vaccination in patients with blood cancers. This study concluded that seroconversion rates in these patients were significantly lower than that of healthy controls. Some background The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)...

Should CAR-T be used earlier for NHL patients?

Posted by Peigi Chace on Jun 9, 2022 in Non-Hodgkin lymphoma |

CAR-T therapy is a relatively new immunotherapy treatment for advanced B-cell lymphomas, including non-Hodgkin’s lymphoma (NHL). It is usually reserved for patients who have had more than one previous line of treatment but relapsed anyway. The standard course of treatment for non-Hodgkin’s lymphoma is chemotherapy, which cures about 70% of...

How effective is non-myeloablative chemotherapy after high-dose methotrexate-based treatment in patients with primary central nervous system lymphoma?

Posted by Medivizor on Jun 1, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of patients with primary central nervous system lymphoma (PCNSL) on high-dose methotrexate (HD-MTX; Otrexup)-based chemotherapy followed by non-myeloablative consolidation therapy. The study showed that HD-MTX-based chemotherapy with non-myeloablative consolidation therapy is an alternative and...

Evaluating COVID-19 vaccination in immunocompromised patients with blood cancers

Posted by Medivizor on May 31, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study aimed to investigate if immunocompromised patients with blood cancers benefit from COVID-19 vaccination. This study concluded that these patients should not be excluded from COVID-19 vaccination. Some background Patients with blood cancers are at high risk for severe forms of COVID-19 disease due to lower immune...

Evaluating the effectiveness of immunochemotherapy treatments for advanced stage follicular lymphoma.

Posted by Medivizor on May 31, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness of common immuno-chemotherapy (ICT) treatments for advanced follicular lymphoma (FL) for front-line therapy. The study showed that obinutuzumab (Gazyva; G) combined with bendamustine (Treanda; Benda) (G-Benda-G regimen) had the best survival without cancer worsening in patients with advanced...

Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

$Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.$

Posted by Medivizor on May 8, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed or refractory (r/r) follicular lymphoma (FL). The data showed that pembrolizumab in combination with rituximab was safe and effective in these patients. Some background Follicular lymphoma (FL)...

Non-Hodgkin lymphoma Posts on Medivizor

Evaluating the effectiveness and safety of polatuzumab vedotin combined with dose-adjusted EPOCH-R chemotherapy in patients with aggressive B-cell non-Hodgkin lymphoma.

Evaluating the effectiveness and safety of zanubrutinib versus ibrutinib in patients with Waldenström Macroglobulinemia.

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

Evaluating the effectiveness and safety of venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma.

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Evaluating response to SARS-CoV-2 vaccination in patients with blood cancers

Should CAR-T be used earlier for NHL patients?

How effective is non-myeloablative chemotherapy after high-dose methotrexate-based treatment in patients with primary central nervous system lymphoma?

Evaluating COVID-19 vaccination in immunocompromised patients with blood cancers

Evaluating the effectiveness of immunochemotherapy treatments for advanced stage follicular lymphoma.

Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

Categories

Recent Posts

Archives

Non-Hodgkin lymphoma Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email